SARC031

A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors

TYPE OF SARCOMA: Unresectable or Metastatic NF1 Associated or Sporadic Malignant Peripheral Nerve Sheath Tumors (MPNST)
DRUG: Selumetinib in Combination with Sirolimus

ACCRUAL STATUS: Not recruiting

OVERALL STUDY PRINCIPAL INVESTIGATORS:
AeRang Kim, MD, PhD
Pediatric Oncologist
Children’s National Health System

Brigitte Widemann, MD
Senior Investigator, Pediatric Oncology Branch
National Cancer Institute

CLINICALTRIALS.GOV IDENTIFIER: NCT03433183

FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICALTRIALS.GOV

To learn more about this study view Dr. Kim’s SARC031 presentation at the 2021 SARC Semiannual Meeting:

To contact the study research staff: